AR107550A1 - Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización - Google Patents

Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización

Info

Publication number
AR107550A1
AR107550A1 ARP170100299A ARP170100299A AR107550A1 AR 107550 A1 AR107550 A1 AR 107550A1 AR P170100299 A ARP170100299 A AR P170100299A AR P170100299 A ARP170100299 A AR P170100299A AR 107550 A1 AR107550 A1 AR 107550A1
Authority
AR
Argentina
Prior art keywords
preparation process
trifluoroacetate
tlr7 agonist
crystal form
tlr7
Prior art date
Application number
ARP170100299A
Other languages
English (en)
Spanish (es)
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of AR107550A1 publication Critical patent/AR107550A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
ARP170100299A 2016-02-05 2017-02-06 Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización AR107550A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610081899.3A CN107043377A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途

Publications (1)

Publication Number Publication Date
AR107550A1 true AR107550A1 (es) 2018-05-09

Family

ID=59500539

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100299A AR107550A1 (es) 2016-02-05 2017-02-06 Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización

Country Status (23)

Country Link
US (1) US10683296B2 (enExample)
EP (1) EP3412674B1 (enExample)
JP (1) JP6877450B2 (enExample)
KR (1) KR102393281B1 (enExample)
CN (2) CN107043377A (enExample)
AR (1) AR107550A1 (enExample)
AU (1) AU2017214135B2 (enExample)
CA (1) CA3013521C (enExample)
CL (1) CL2018002101A1 (enExample)
DK (1) DK3412674T3 (enExample)
EA (1) EA037048B1 (enExample)
ES (1) ES2834304T3 (enExample)
HU (1) HUE052210T2 (enExample)
IL (1) IL260981B (enExample)
MX (1) MX374300B (enExample)
MY (1) MY198137A (enExample)
NZ (1) NZ745023A (enExample)
PH (1) PH12018501641B1 (enExample)
SG (1) SG11201806688QA (enExample)
TW (1) TWI778952B (enExample)
UA (1) UA121276C2 (enExample)
WO (1) WO2017133687A1 (enExample)
ZA (1) ZA201805240B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
EP3414239A2 (en) 2016-02-05 2018-12-19 Denali Therapeutics Inc. Inhibitors of receptor-interacting protein kinase 1
JP7385602B2 (ja) * 2018-05-25 2023-11-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 肺癌を治療するためのtlr7アゴニストおよびその医薬の組み合わせ
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途
CA3170551A1 (en) 2020-03-02 2021-09-10 Yong Taik Lim Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
EP4194010A4 (en) 2020-08-04 2025-03-26 Progeneer Inc. Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
BRPI0923305B1 (pt) 2008-12-09 2019-01-22 Gilead Sciences Inc moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
CA2826295C (en) * 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2013103967A1 (en) * 2012-01-05 2013-07-11 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
PT2906563T (pt) * 2012-10-10 2018-05-23 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças
EP2922550B1 (en) * 2012-11-20 2017-04-19 Glaxosmithkline LLC Novel compounds
PT3137470T (pt) * 2014-05-01 2021-06-24 Novartis Ag Compostos e composições como agonistas do recetor tipo toll 7
KR20160144399A (ko) * 2014-05-01 2016-12-16 노파르티스 아게 톨-유사 수용체 7 효능제로서의 화합물 및 조성물
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
UA117634C2 (uk) * 2014-08-15 2018-08-27 Чиа Тай Тяньцін Фармасьютикал Ґруп Ко., Лтд. Піролопіримідинові сполуки, що використовуються як агоніст tlr7
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂

Also Published As

Publication number Publication date
CA3013521C (en) 2022-07-12
US20190031666A1 (en) 2019-01-31
EA037048B1 (ru) 2021-01-29
PH12018501641B1 (en) 2021-03-26
EP3412674B1 (en) 2020-09-16
US10683296B2 (en) 2020-06-16
JP6877450B2 (ja) 2021-05-26
MX2018009503A (es) 2018-12-11
ZA201805240B (en) 2024-09-25
HUE052210T2 (hu) 2021-04-28
BR112018015878A2 (pt) 2018-12-26
AU2017214135B2 (en) 2020-08-13
TW201728591A (zh) 2017-08-16
CN108602833A (zh) 2018-09-28
WO2017133687A1 (zh) 2017-08-10
IL260981B (en) 2022-05-01
JP2019504103A (ja) 2019-02-14
SG11201806688QA (en) 2018-09-27
PH12018501641A1 (en) 2019-06-03
AU2017214135A1 (en) 2018-08-23
EP3412674A1 (en) 2018-12-12
UA121276C2 (uk) 2020-04-27
EP3412674A4 (en) 2019-07-17
ES2834304T3 (es) 2021-06-17
CA3013521A1 (en) 2017-08-10
HK1259182A1 (zh) 2019-11-29
MY198137A (en) 2023-08-07
CL2018002101A1 (es) 2018-12-07
KR102393281B1 (ko) 2022-05-02
CN108602833B (zh) 2020-07-28
KR20180104118A (ko) 2018-09-19
MX374300B (es) 2025-03-06
EA201891772A1 (ru) 2019-01-31
NZ745023A (en) 2022-09-30
DK3412674T3 (da) 2020-11-09
CN107043377A (zh) 2017-08-15
TWI778952B (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
AR107550A1 (es) Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
BR112015005404A2 (pt) Formas polimórficas de enzalutamida e sua preparação
UY36226A (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
ECSP18010481A (es) Composiciones de plinabulina
MX2015014081A (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor de canabinoides 2 (cb2).
CL2018002094A1 (es) Un proceso para preparar compuesto de pirrolo[3,2–d]pirimidina y su intermediario
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
MX382724B (es) Formas sólidas de ceftolozano.
UY35610A (es) Derivados de prodroga de triazolpiridinas sustituidas
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
RU2014118884A (ru) Средство для снижения алкогольной мотивации при алкогольной зависимости
CO2017002070A2 (es) Un proceso para la preparación de derivados de 3-fenil/heteroaril-6-fenoxi-8-alquilamino-imidazo[1,2-b] piridazina
UY35347A (es) Formas cristalinas de un inhibidor de la prolil hidroxilasa
MX2017006679A (es) Formas cristalinas de inhibidores de poli adp-ribosa polimerasa (parp).

Legal Events

Date Code Title Description
FC Refusal